A 71-Year-Old Woman with NTRK Gene Fusion Thyroid Cancer

Video

A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.

Case: A 71-Year-Old Woman With Thyroid NTRK Gene Fusion Cancer

Initial Presentation

  • A 71-year-old woman presents with a painless “ball on his neck”
  • PMH: hypercholesterolemia, medically controlled
  • PE: palpable, non-tender solitary left-of-the midline neck mass; otherwise unremarkable


Clinical Workup and Initial Treatment

  • Labs: including TSH, anti-Tg antibodies WNL
  • Ultrasound of the neck revealed a 3.8 cm suspicious mass arising from the left thyroid; 4 suspicious submandibular lymph nodes, largest 2.2 cm in size
  • Ultrasound-guided FNAB of the thyroid mass and the largest lymph node confirmed undifferentiated papillary thyroid carcinoma
  • Chest/abdominal/pelvic CT showed no evidence of distant metastases
  • Patient underwent total thyroidectomy with therapeutic central compartment and left selective neck dissection
    • Pathology: 3.8 cm undifferentiated papillary thyroid cancer arising in left lobe of thyroid, 2 of 7 positive central compartment lymph nodes, largest 1.3 cm, no extra nodal extension
  • StageT2N1M1; ECOG PS 0

Follow-Up and Additional Treatment

  • She was treated with radioactive iodine 150 millicuries
    • Whole body scan showed uptake in neck only consistent with thyroid remnant
    • Added levothyroxine to regimen
  • Follow-up at 2 months TSH 0.2 mU/L; thyroglobulin 26 ng/mL
    • MRI of the brain revealed multiple small lesions
  • Biomarkers testing:NTRK fusion+, RET-, BRAF-, NRAS-,KRAS-
  • Initiated treatment with larotrectinib 100 mg PO BID
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content